Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827023 | 0.74 | CYP1A2 (0.46) | CYP1A2CYP2D6KDM4ETSHR | |
| SCHEMBL5217076 | 0.74 | PARP1 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL7511701 | 0.71 | CYP1A2 (0.47) | CYP1A2CYP2D6TSHR | |
| SCHEMBL4495878 | 0.70 | ATM (0.61) | KDM4E | |
| SCHEMBL2449027 | 0.69 | KDM4E (0.49) | CYP1A2CYP2D6KDM4E | |
| SCHEMBL27381193 | 0.68 | TSHR (0.44) | CYP1A2CYP2D6TSHR | |
| SCHEMBL6343186 | 0.68 | CYP1A2 (0.49) | CYP1A2CYP2D6 | |
| SCHEMBL2126594 | 0.67 | — | — | |
| SCHEMBL6988130 | 0.67 | TSHR (0.56) | TSHR | |
| SCHEMBL3784364 | 0.66 | HPGD (0.49) | KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046336-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008011045-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP2 | CYP1A2 97/4885CYP2D6 441/4885KDM4E 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.